A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

February 20, 2019

Primary Completion Date

June 2, 2020

Study Completion Date

June 2, 2020

Conditions
Crohn Disease
Interventions
DRUG

GSK1070806

GSK1070806 100mg/ml injectable solution will be delivered via intravenous infusion as a single infusion

DRUG

Placebo- sodium chloride

Placebo injectable solution will be delivered via intravenous infusion as a single infusion

Trial Locations (1)

B15 2TH

University Hospitals Birmingham NHS Foundation Trust, Birmingham

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

GlaxoSmithKline

INDUSTRY

collaborator

University Hospital Birmingham

OTHER

lead

University of Birmingham

OTHER

NCT03681067 - A Clinical Trial of Antibody GSK1070806 in the Treatment of Patients With Moderate to Severe Crohn's Disease | Biotech Hunter | Biotech Hunter